Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 92
Tesamorelin: what experts said, Q2 2026
Tesamorelin has one FDA approval and plenty of off-label hype. Here is what named experts said this quarter.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
What experts said about BPC-157 in Q2 2026
A digest of on-record expert commentary on BPC-157 from Q2 2026, with credentials, conflicts of interest, and the evidence gaps each expert flagged.
What experts said about CJC-1295 in Q2 2026
On-record expert commentary on CJC-1295 from Q2 2026: the evidence gap, cancer-risk concerns, regulatory shifts, and the upcoming PCAC review.
Ipamorelin: what experts said, Q2 2026
On-record expert commentary on ipamorelin from Q2 2026, with credentials, conflicts of interest, and the FDA regulatory picture.
Oral semaglutide for weight loss, reviewed
A Postgraduate Medicine review examines the trial evidence, dosing requirements, and practical considerations for using oral semaglutide in weight management.
Peptides for nerve recovery after surgery
BPC-157, TB-500, and ARA 290 are discussed in recovery communities after nerve surgery. Here is what preclinical and early clinical evidence actually shows.
What experts said about PT-141 in Q2 2026
On-record expert commentary on PT-141 from Q2 2026: arguments for male trials, a Harvard meta-analysis, and Palatin's obesity pivot.
Why your Semax or Selank spray smells off
A fishy or sulfurous smell from a pre-mixed peptide nasal spray usually signals degradation. The methionine chemistry explains why.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
BPC-157 tested as AChE inhibitor in vitro
A 2026 lab study finds BPC-157 and two hybrid peptides inhibit the enzyme targeted by Alzheimer's drugs, but at low potency and only in vitro.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.